Navigation Links
Pharmaceutical Product Launch: Commercially Focused R&D Increases Drug's Market Potential
Date:10/9/2007

CHAPEL HILL, N.C., Oct. 9 /PRNewswire/ -- Pharmaceutical and biotech companies reach much greater and sustained product success when they ensure strong partnerships between R&D and marketing, balancing therapeutic innovation with commercial focus in all stages of product development.

It requires companies to break down the walls that have traditionally separated R&D from marketing and instead leverage the strengths of both talented medical researchers and skillful marketers.

Best Practices LLC's benchmarking report, "Best Practices in Global Pharmaceutical Launches," outlines just what commercially focused R&D looks like.

Analysts harvested survey data and qualitative best practices from informed executives at elite pharmaceutical companies, including Merck, Pfizer, Johnson & Johnson, Bristol-Myers Squibb and Novartis. The report includes over 180 metrics, 100 best practices and 20 company narratives on critical pre and post launch topics, including:

* Marketing Launch Strategy and Structure

* Marketing Investment and Staffing

* Cross-Functional Launch Team Composition and Management

* Thought Leader Development

* Sales Force Support and Compensation Management

* Market Research

* Marketing Activities

* Life Cycle Management

For more information, sample practices and graphics from this report, download a complimentary excerpt at http://www3.best-in-class.com/rr864.htm.

Example best practices from the report include:

* The most successful product launches reveal new levels of organizational

alignment. Marketers play a vital role in shaping and planning product

strategy. Marketing activities are beginning earlier in the development

process - often four to six years prior to launch.

* Top-performing benchmark partners invested significant financial and

human resources to ensure the initial and on-going success of important

new products. For a blockbuster drug with potential annual sales of at

least $500 million ~ $1 billion within 3-4 years following launch, these

companies spent between $100 million and $500 million in marketing

dollars.

* Benchmark partners stressed the importance of managing thought leader

development as an integrated, multi-phased process. Companies seek to

tailor their efforts, activities and relationship investments to match

the value of each thought leader segment and to reflect the roles of

each segment at different points in time.

Product and marketing executives seeking to improve their own drug launch process will find this detailed report invaluable for learning how the best in the world do it. By implementing the basic drug launch formulas of best-in- class organizations, companies can fine-tune their products' positioning with added assurances of success.

Download additional findings in the complimentary report summary at: http://www3.best-in-class.com/rr864.htm or contact our Solution Specialists at (919) 403-0251 or bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies. Visit us online at www3.best-in-class.com.


'/>"/>
SOURCE Best Practices LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
3. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
4. Deltanoid Pharmaceuticals begins phase II osteoporosis study
5. Doing the pharmaceutical tango
6. Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for
7. The Coming of Biotech Generic Pharmaceuticals
8. Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies
9. A New C-Terminal GST Vector for Protein Production in S. pombe
10. Safe Production of High-Titer Retrovirus
11. Production of Full-Length, Biologically Active MEK1WT and MEK1CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):